Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | COMT | P21964 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142617 | 0.88 | MAPT (0.43) | NOTUMATMCOMTALDH1A1KDM4E | |
| SCHEMBL14018033 | 0.82 | PTGS2 (0.45) | ALDH1A1KDM4EMAPTLMNAPTGS1 | |
| SCHEMBL13153504 | 0.82 | FAAH (0.38) | NOTUMALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL9109139 | 0.82 | MMP8 (0.42) | ALDH1A1HPGDMAPTMEN1KMT2A | |
| SCHEMBL3834300 | 0.82 | ALDH1A1 (0.40) | ATMALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL9292198 | 0.81 | HSP90AA1 (0.49) | NOTUMALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL1344141 | 0.80 | TRPV1 (0.43) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL31456729 | 0.80 | CYP2A6 (0.53) | ALDH1A1HSD17B10KAT2BMAPTEP300 | |
| SCHEMBL4282578 | 0.78 | HTT (0.51) | NOTUMCYP1A2MAPTMEN1KMT2A | |
| SCHEMBL30613481 | 0.78 | COMT (0.49) | NOTUMATMCOMTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514348-A2 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | Noetix Pharma LLC (US) | 2025-03-05 | — | — | EP | claimed |
| US-20240299698-A1 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | NOETIX PHARMA LLC | 2024-09-12 | — | — | US | claimed |
| WO-2023211684-A2 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | NOETIX PHARMA LLC (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | claimed |
| CN-108883072-A | Granular preparation of 5-methyl-1-phenyl-2- (1H) -pyridone and preparation method thereof | 霍夫曼-拉罗奇有限公司 | 2018-11-23 | — | — | CN | claimed |
| US-20180243277-A1 | GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AND METHOD OF MAKING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2018-08-30 | — | — | US | claimed |
| US-8753679-B2 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | INTERMUNE, INC. (US) | 2014-06-17 | — | — | US | claimed |
| US-8287900-B2 | Medicated patch comprising 5-methyl-1-phenyl-2-(1H)-pyridone | LEAD CHEMICAL CO., LTD. (JP) | 2012-10-16 | — | — | US | claimed |
| EP-2431025-A1 | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | Intermune, Inc. (US) | 2012-03-21 | — | — | EP | claimed |
| US-7605173-B2 | Pharmaceutical liquid composition containing pyridone derivative | KDL, INC. (JP) | 2009-10-20 | — | — | US | claimed |
| EP-1539155-B1 | STABLE CREAM PREPARATIONS OF PHENYL-PYRIDONE COMPOUNDS FOR TOPICAL APPLICATION | MEPHA AG (CH) | 2008-04-02 | — | — | EP | claimed |
| EP-0866656-B1 | USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS | MARGOLIN SOLOMON B (US) | 2007-04-25 | — | — | EP | claimed |
| US-20060039931-A1 | Stable cream preparations of phenyl-pyridone compounds for topical application | MEPHA AG (CH) | 2006-02-23 | — | — | US | claimed |
| EP-1138329-B1 | Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions | YAMAUCHI SHITOTOMO (JP) | 2004-06-02 | — | — | EP | claimed |
| EP-1069898-B1 | TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS | MARGOLIN SOLOMON B (US) | 2004-05-12 | — | — | EP | claimed |
| EP-0813409-B1 | TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS | MARGOLIN SOLOMON B (US) | 2004-05-06 | — | — | EP | claimed |
| EP-0702551-B1 | COMPOSITIONS AND METHODS FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS | MARGOLIN SOLOMON B (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1138329-A2 | Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions | Yamauchi, Shitotomo (JP) | 2001-10-04 | — | — | EP | claimed |
| US-5962478-A | ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE | INTERMUNE, INC. | 1999-10-05 | — | — | US | claimed |
| US-20250367178-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250213539-A1 | METHODS OF USING A PHARMACEUTICAL COMPOSITION CONTAINING PIRFENIDONE IN SUSTAINED-RELEASE TABLET FORM | EXCALIBUR PHARMACEUTICALS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4551204-A2 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | Pliant Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250114376-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4514348-A2 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | Noetix Pharma LLC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-12226407-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4491180-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | Avalyn Pharma Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240299698-A1 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | NOETIX PHARMA LLC | 2024-09-12 | — | — | US | disclosed |
| US-12083106-B2 | Methods of using a pharmaceutical composition containing pirfenidone in sustained-release tablet form | EXCALIBUR PHARMACEUTICALS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024155965-A2 | BIOMARKERS FOR USE IN INTEGRIN INHIBITOR THERAPY | PLIANT THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| EP-3091976-B1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-12023342-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240122930-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-111372945-B | Treatment of idiopathic pulmonary interstitial fibrosis based on oxyntomodulin analog GLP-1R/GCGR dual-target agonist polypeptides | 中山大学 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024015717-A2 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023211684-A2 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | NOETIX PHARMA LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-2877164-B1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS | AVALYN PHARMA INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230149375-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2023-05-18 | — | — | US | disclosed |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11452718-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-4059499-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | Avalyn Pharma Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220218683-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2022-07-14 | — | — | US | disclosed |
| US-11224592-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210346399-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2021-11-11 | — | — | US | disclosed |
| US-11071741-B2 | Aerosol pirfenidone and pyridone analog compound and uses thereof | AVALYN PHARMA INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200405704-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200306264-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUND AND USES THEREOF | AVALYN PHARMA INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-10610536-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190054076-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2019-02-21 | — | — | US | disclosed |
| US-20190030012-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180325917-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10105356-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2018-10-23 | — | — | US | disclosed |
| CN-108699037-A | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | 加拉帕戈斯股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| US-10092552-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-10028966-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-9770443-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | GENOA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170224706-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| EP-3091976-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | Genoa Pharmaceuticals Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9408836-B2 | Pharmaceutical composition containing pirfenidone in sustained-release tablet form | Cell Therapy and Technology S.A. DE C.V. (MX) | 2016-08-09 | — | — | US | disclosed |
| US-20150196543-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2015-07-16 | — | — | US | disclosed |
| WO-2015106150-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| EP-2877164-A2 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS | Genoa Pharmaceuticals, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20140296300-A1 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION CONTAINING PIRFENIDONE IN SUSTAINED-RELEASE TABLET FORM AND ITS APPLICATION IN THE REGRESSION OF HUMAN CHRONIC RENAL FAILURE, BREAST CAPSULAR CONTRACTURE AND HEPATIC FIBROSIS | Cell Therapy and Technology S.A. DE C.V. (MX) | 2014-10-02 | — | — | US | disclosed |
| CN-103735530-A | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | INTERMUNE INC | 2014-04-23 | — | — | CN | disclosed |
| WO-2014018668-A2 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| EP-2670242-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | Genoa Pharmaceuticals, Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130310424-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2013-11-21 | — | — | US | disclosed |
| CN-103393607-A | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | INTERMUNE INC | 2013-11-20 | — | — | CN | disclosed |
| WO-2012106382-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8063055-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7700607-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2010-04-20 | — | — | US | disclosed |
| WO-2009149188-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1539155-B1 | STABLE CREAM PREPARATIONS OF PHENYL-PYRIDONE COMPOUNDS FOR TOPICAL APPLICATION | MEPHA AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-20070092488-A1 | Methods of treating idiopathic pulmonary fibrosis | INTERMUNE INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070072181-A1 | Combination therapy for treating alphavirus infection and liver fibrosis | CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT | 2007-03-29 | — | — | US | disclosed |
| US-20060198823-A1 | Compositions and methods for treating viral infections | INTERMUNE, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1261338-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY | CYMAR INC (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060039931-A1 | Stable cream preparations of phenyl-pyridone compounds for topical application | MEPHA AG (CH) | 2006-02-23 | — | — | US | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| US-6956044-B1 | Compositions and methods for treatment of epilepsy | INTERMUNE, INC. | 2005-10-18 | — | — | US | disclosed |
| EP-0702551-B1 | COMPOSITIONS AND METHODS FOR REPARATION AND PREVENTION OF FIBROTIC LESIONS | MARGOLIN SOLOMON B (US) | 2002-09-25 | — | — | EP | disclosed |
| US-5962478-A | ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE | INTERMUNE, INC. | 1999-10-05 | — | — | US | disclosed |
| US-4052509-A | 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE | AFFILIATED MEDICAL RESEARCH, INC. (US) | 1977-10-04 | — | — | US | disclosed |
| US-4042699-A | 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE | AFFILIATED MEDICAL RESEARCH, INC. (US) | 1977-08-16 | — | — | US | disclosed |
| US-3974281-A | ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS | AFFILIATED MEDICAL RESEARCH, INC. (US) | 1976-08-10 | — | — | US | disclosed |
| US-3974281-A | ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS | AFFILIATED MEDICAL RESEARCH, INC. (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (38 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10105356-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | NOTUM 2635/4885ATM 4224/4885COMT 3198/4885 |
| US-20230149375-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20240299698-A1 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | CHAT, PNPO, PLPBP | NOTUM 2178/4885ATM 293/4885COMT 15/4885 |
| US-20100160312-A1 | Substituted Pyridone Compounds and Methods of Use | KIT, CMA1, C3AR1 | NOTUM 3661/4885ATM 2083/4885COMT 3171/4885 |
| US-10610536-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-11224592-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | ITGB6, ITGA5, ITGAV | NOTUM 4179/4885ATM 3420/4885COMT 4803/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | NOTUM 2635/4885ATM 4224/4885COMT 3198/4885 |
| US-20240122930-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | ITGB6, ITGA6, ITGAV | NOTUM 1834/4885ATM 4226/4885COMT 4604/4885 |
| US-20210069165-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20070092488-A1 | Methods of treating idiopathic pulmonary fibrosis | IFNG, MMP1, IFNAR1 | NOTUM 4102/4885ATM 2914/4885COMT 4709/4885 |
| US-20150196543-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | NOTUM 4398/4885ATM 598/4885COMT 2075/4885 |
| US-20060198823-A1 | Compositions and methods for treating viral infections | IFNAR1, IFNG, TLR3 | NOTUM 4268/4885ATM 3974/4885COMT 4118/4885 |
| US-20220218683-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20200405704-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20200306264-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUND AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4418/4885ATM 3168/4885COMT 4769/4885 |
| US-10028966-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20250114376-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20060039931-A1 | Stable cream preparations of phenyl-pyridone compounds for topical application | PNPO, APOB, PLPBP | NOTUM 330/4885ATM 2801/4885COMT 2625/4885 |
| US-20250367178-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20190054076-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-11452718-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20170224706-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | NOTUM 2635/4885ATM 4224/4885COMT 3198/4885 |
| US-20210346399-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-12023342-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20080249090-A1 | Substituted pyridone compounds and methods of use | KIT, CMA1, C3AR1 | NOTUM 3661/4885ATM 2083/4885COMT 3171/4885 |
| US-20180325917-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | NOTUM 2635/4885ATM 4224/4885COMT 3198/4885 |
| US-20190030012-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-10092552-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-12226407-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-20130310424-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | NOTUM 4443/4885ATM 3312/4885COMT 4769/4885 |
| US-11071741-B2 | Aerosol pirfenidone and pyridone analog compound and uses thereof | PLPBP, PIR, PDXK | NOTUM 4418/4885ATM 3168/4885COMT 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.